Table 2 Assessment of LV diastolic function via PW Doppler and tissue Doppler echocardiography
From: Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction
| Â | Non-diabetic mice | Diabetic mice | ||
|---|---|---|---|---|
Vehicle | LXA4 | Vehicle | LXA4 | |
PW Doppler and tissue Doppler echocardiography | ||||
N | 12 | 16 | 8 | 13 |
Heart rate (bpm) | 434 ± 9 | 421 ± 8 | 384 ± 12# | 427 ± 8** |
Peak E wave velocity (mm/s) | 788 ± 24 | 760 ± 18 | 731 ± 38 | 709 ± 18 |
Peak A wave velocity (mm/s) | 505 ± 32 | 467 ± 15 | 405 ± 21^ | 427 ± 10 |
Peak e’ velocity (mm/s) | 23.9 ± 1.1 | 25.0 ± 0.7 | 23.4 ± 2.3 | 20.7 ± 1.3$ |
Peak a’ velocity (mm/s) | 22.6 ± 1.1 | 21.4 ± 0.7 | 20.5 ± 0.9 | 21.5 ± 0.6 |
E/A ratio | 1.62 ± 0.08 | 1.64 ± 0.05 | 1.83 ± 0.14 | 1.67 ± 0.06 |
e’/a’ ratio | 1.09 ± 0.09 | 1.19 ± 0.05 | 1.15 ± 0.14 | 0.95 ± 0.06$ |
E/e’ ratio | 33.7 ± 2.0 | 30.8 ± 1.1 | 32.4 ± 1.8 | 35.7 ± 2.1$ |
Deceleration time (ms) | 15.4 ± 0.3 | 17.1 ± 0.7 | 26.4 ± 2.2## | 21.0 ± 0.9**, $$ |
Isovolumetric relaxation time (ms) | 14.3 ± 0.6 | 15.1 ± 0.6 | 17.1 ± 1.0# | 15.1 ± 0.4* |